Skip to content
Clinical Trials – home
Not yet recruitingRare disease

Phase 2 Study of MAR002 to Assess Safety and IGF‑1 Reduction in Adults with Acromegaly

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

What is this trial about?

A plain-language summary of the goals, design and what participants do

Acromegaly is a rare condition in which the body produces too much growth hormone, causing the bones and soft tissues to enlarge, often leading to noticeable changes in facial features, hands, and feet. The study is testing a new medication called MAR002, which is given as a liquid injection under the skin, and it will be compared with a placebo, a substance that looks the same but does not contain the active drug.

The purpose of the study is to determine whether multiple doses of MAR002 are safe and can lower the level of IGF-1 in the blood, a protein that reflects how much growth hormone is active in the body, and to see if symptoms improve. Safety checks will include physical examinations, heart rhythm monitoring, and laboratory tests, while symptom improvement will be measured with questionnaires and doctor assessments.

Participants will receive a series of injections over several weeks, with regular clinic visits to monitor health, draw blood samples for the IGF-1 test, and complete symptom questionnaires. The study continues until the final visit, which occurs after the last dose, and then all data are collected for analysis.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Enrollment and Baseline Assessments

    After joining the study, you will sign an informed consent form and provide your medical history.

    A physical examination, measurement of vital signs, and an electrocardiogram (ECG) will be performed.

    Blood samples will be taken to measure baseline serum IGF-1 levels and to conduct safety laboratory tests.

    You will complete questionnaires that evaluate acromegaly symptoms, such as the AcroQoL and ASD scales, and your ring size will be recorded.

  2. Step 2

    Randomization and First Injection

    You will be randomly assigned to receive either the study drug MAR002 or a matching placebo.

    The assigned product will be administered by a subcutaneous (SC) injection of a solution for injection.

    The specific dose is determined by the study protocol; the injection is given at the first study visit.

  3. Step 3

    Scheduled Follow‑up Visits and Additional Injections

    You will return to the clinic at regular intervals for additional SC injections of the assigned product.

    At each visit, vital signs, a brief physical exam, and safety laboratory tests will be repeated.

    An ECG may be performed, and any adverse events will be recorded.

    The schedule includes visits up to week 10, with injections typically given every two weeks.

  4. Step 4

    Mid‑Study Assessments (Week 8)

    During the week 8 visit, blood will be drawn to measure serum IGF-1 levels.

    You will again complete the AcroQoL and ASD questionnaires to assess symptom changes.

    Safety evaluations, including laboratory tests and vital signs, will be performed.

  5. Step 5

    End‑of‑Study Assessments (Week 10)

    A final injection of the assigned product will be administered.

    Blood samples will be collected to determine serum IGF-1 levels for the primary efficacy analysis.

    You will complete the symptom questionnaires and have your ring size measured again.

    A comprehensive safety assessment, including vital signs, physical exam, ECG, and laboratory tests, will be completed.

    All study procedures will conclude at this visit, marking the end of the trial for you.

Who can join the trial?

6 criteria

  • Willing to give written informed consent (a signed form showing you understand the study) and follow all study procedures.
  • Age between 18 and 75 years and have active acromegaly confirmed by a specialist doctor called an endocrinologist who treats pituitary problems. You must have documentation of a pituitary tumor (a growth in the pituitary gland) shown by an imaging test such as MRI (magnetic resonance imaging) or CT (computerized tomography) scan, or by tissue examination after surgery, and a history of high blood levels of IGF-1 (a hormone that is often elevated in acromegaly).
  • If you are currently taking medication for acromegaly, the doctor must consider your treatment stable and you must agree to stop (a “washout”) those medicines before beginning the study.
  • Your average blood level of IGF-1 must be at least 1.3 times the upper limit of normal (ULN). This is calculated from two separate tests taken at least one week apart.
  • If you have hypothyroidism (underactive thyroid) or adrenal insufficiency (underactive adrenal glands), these hormone problems must be adequately treated as judged by the doctor.
  • Your weight must be at least 50 kg at the screening visit.

Who cannot join the trial?

22 criteria

  • History of hypersensitivity (allergic reaction) to monoclonal antibodies (lab‑made protein medicines) means you cannot join.
  • Being pregnant or breastfeeding excludes you from the study.
  • Male participants who plan to donate sperm, or who have a partner planning to become pregnant during the study and for 90 days after the last dose, cannot take part.
  • If you have diabetes and have been using insulin for less than 6 weeks before the study, or if your insulin dose has been changing frequently during that time, you are not eligible.
  • People whose blood level of IGF‑1 is already controlled (≤ 1 × upper‑limit‑of‑normal) while taking certain hormone medicines (either a single somatostatin‑receptor ligand (SRL), a single dopamine agonist (DA), or a combination of SRL + DA) cannot join.
  • Anyone currently taking a combination of SRL, DA, and the drug pegvisomant (whether the disease is controlled or not) is excluded.
  • If you have taken part in another experimental drug study and received the last dose less than about 60 days ago (or a longer period based on the drug’s half‑life), you cannot participate.
  • A history of severe allergic or anaphylactic reactions (a sudden, serious allergic response) disqualifies you.
  • Having a cancer diagnosis within the past 5 years excludes you, except for certain skin cancers (basal or squamous cell) or localized cervical cancer that were successfully treated, and in‑situ cancers treated within 2 years.
  • Any pituitary surgery in the 6 months before screening, or previous pituitary radiation therapy, makes you ineligible.
  • If your pituitary tumor (adenoma) is thought to press on the optic nerve or other important structures, you cannot join.
  • Uncontrolled diabetes, defined as a hemoglobin A1c (a blood test that shows average sugar level) of 9.0 % or higher, excludes you.
  • A significant illness that has not fully resolved at least 2 weeks before randomization prevents participation.
  • Any condition that makes it unsafe to have an MRI scan—such as certain metal implants, electronic devices, severe claustrophobia, large body size, or tattoos that are not MRI‑safe—excludes you.
  • Any health problem that, in the investigator’s opinion, would stop you from following study procedures, completing the study, or could affect the study results, makes you ineligible.
  • Severe kidney problems (estimated glomerular filtration rate < 30 mL/min/1.73 m²) or serious liver disease (liver enzymes more than 3 times the normal limit or bilirubin more than 2 times normal, including advanced cirrhosis) prevent enrollment.
  • Having a heart attack, heart surgery (such as bypass or angioplasty), hospitalization for heart failure, stroke, or a mini‑stroke (transient ischemic attack) within the past 12 months excludes you.
  • High blood pressure while lying down (systolic > 160 mm Hg or diastolic > 100 mm Hg) measured at screening (average of three readings) disqualifies you.
  • Known uncontrolled HIV infection prevents participation.
  • Active hepatitis A, B, or C infection (including untreated viral hepatitis) excludes you.
  • Donating 450 mL (about one pint) or more of blood within the 3 months before the first study day makes you ineligible.
  • Not agreeing to use the required contraception: biological males must use a condom (even if vasectomized) for the study period and 90 days after the last dose; women who could become pregnant must use two methods of birth control (one highly effective and one additional effective method) starting 28 days before the first dose, during the study, and for 180 days after the last dose, and must have a negative pregnancy test at screening.
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

MAR002 is an experimental medication being tested in this study. It is a liquid that is injected under the skin (subcutaneous injection). The purpose of giving MAR002 to participants with acromegaly is to see if it can safely lower the level of a hormone called IGF‑1, which is often too high in this condition. Researchers will give several doses of MAR002 over time to evaluate how well the body tolerates it, how it moves through the body, and how it affects the disease‑related hormone levels. This information will help determine whether MAR002 might become a useful treatment for people with acromegaly.

What is already known about the treatment

MAR002 - This medication is given as a sterile solution for injection, administered under the skin in multiple doses. It is currently an experimental drug that is being studied in clinical trials and has not yet received regulatory approval. The main use being tested is to treat acromegaly, a condition where excess growth hormone raises IGF‑1 levels. It works by attaching to the growth‑hormone pathway and lowering the production of IGF‑1, and it is classified as an investigational biologic agent.

Investigated diseases

Acromegaly - Acromegaly is a hormonal disorder caused by excess growth hormone, most often due to a benign pituitary tumor. The excess hormone leads to gradual enlargement of bones and soft tissues, especially in the hands, feet, and face. Patients may notice swelling of facial features, thickening of skin, and joint discomfort that develop over months to years. The condition typically progresses slowly, with continued tissue growth if the hormone excess persists. Over time, the physical changes become more noticeable and can affect daily activities.
Trial detailsLast updated 20 Nov 2026
Age18+ yearsPhasePhase IITrial ID2026-526340-12-00Protocol codeMAR-202Estimated enrolment60 patientsSponsorMarea Therapeutics Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.